The recently released joint EULAR and Paediatric Rheumatology European Society (PReS) guidelines recommend treatment with IL-1 inhibitors (anakinra or canakinumab) or IL-6 receptor (IL-6R) inhibitors (tocilizumab) for patients with sJIA/AOSD; for patients with high disease activity, concomitant glucocorticoid administration may be required to achieve disease control and tapered when possible [1]. Here, IL1B is linked to adult-onset Still disease.